Simulations Plus Stock News

U.S. stock futures were lower this morning, with the Nasdaq futures falling around 0.2% on Wednesday.

Simulations Plus, Inc. (NASDAQ:SLP ) Q3 2024 Earnings Conference Call July 2, 2024 5:00 PM ET Company Participants Lisa Fortuna - Investor Relations, Financial Profiles Shawn O'Connor - Chief Executiv

Simulations Plus (SLP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus CEO, Shawn O'Connor, will be participating in Morgan Stanley's 3rd Annual Life Sciences AI Summit on June 26, 2024, in New York City.

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will report 3rd quarter FY24 earnings and host a conference call to discuss the financial results on July 2, 2024, at 5pm EDT.

Simulations Plus (SLP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Simulation Plus (SLP) acquires Pro-ficiency from QHP Capital for $100 million in an all-cash transaction.

RALEIGH, N.C.--(BUSINESS WIRE)--QHP Capital-Backed Pro-ficiency Acquired by Simulations Plus.

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced the acquisition of Pro-ficiency with simulation-enabled solutions to expand and enhance the Company's offerings.

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus CEO, Shawn O'Connor, will be participating in Craig-Hallum's 21st Annual Institutional Investor Conference on May 29, in Minneapolis.

Simulations Plus (SLP) unveils GastroPlus X, which significantly reduces time spent on model setup, data management, and reformatting results.

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced the release of the completely redesigned GastroPlusX (GPX), the next generation PBPK/PBBM modeling & simulation software.

You may have heard about GPT-4 Turbo, Gemini, Llama or X's (formerly Twitter) Grok. However, there is a new contender outside of these Big Tech models in town.

For the seventh consecutive year, the FDA has renewed Simulations Plus' (SLP) license to the DILIsym software system for facilitating drug safety evaluations.

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced the US FDA has again renewed licenses to its DILIsym QST software to support informed decision-making in drug approvals.